Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device

Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer

(2015) Kyung Park et al.   NEOPLASIA

Effects of EpCAM overexpression on human breast cancer cell lines

(2011) Johanna M Gostner et al.   BMC CANCER

The Evolving War on Cancer

(2011) Daniel A. Haber et al.   CELL

Circulating Tumor Cells as Biomarkers in Prostate Cancer

(2011) D. C. Danila et al.   CLINICAL CANCER RESEARCH

Circulating tumor cells: approaches to isolation and characterization

(2011) Min Yu et al.   JOURNAL OF CELL BIOLOGY

Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal

(2011) Angela Gradilone et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Circulating Tumor Cells: Not All Detected Cells Are Bad and Not All Bad Cells Are Detected

(2011) Max S. Wicha et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Mitosis is not a key target of microtubule agents in patient tumors

(2011) Edina Komlodi-Pasztor et al.   Nature Reviews Clinical Oncology

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer

(2010) F. A. W. Coumans et al.   ANNALS OF ONCOLOGY

Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells

(2010) Sabine Riethdorf et al.   Annals of the New York Academy of Sciences

Circulating tumor cells: a window into cancer biology and metastasis

(2010) Shyamala Maheswaran et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Utilizing circulating tumor cells: challenges and pitfalls

(2010) Gerhardt Attard et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

(2010) S. L. Stott et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer

(2010) S. L. Stott et al.   Science Translational Medicine

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

(2009) M. Munz et al.   CANCER RESEARCH

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers

(2009) Michael C. Haffner et al.   HUMAN PATHOLOGY

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

(2009) Jason P. Gleghorn et al.   LAB ON A CHIP

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

(2009) Howard I Scher et al.   LANCET ONCOLOGY

Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer

(2009) Hildo J.K. Ananias et al.   PROSTATE

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer

(2008) Steven J. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity

(2008) G Attard et al.   JOURNAL OF CLINICAL PATHOLOGY